ArticleJournal of hepato-biliary-pancreatic sciences2013
Factors predicting survival after post-transplant hepatocellular carcinoma recurrence.
Article in Journal of hepato-biliary-pancreatic sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.World journal of gastroenterology · 2015Pooled it
- SIMAP500: A novel risk score to identify recipients at higher risk of hepatocellular carcinoma recurrence following liver transplantation.World journal of transplantation · 2024Article
- AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation.Journal of hepatology · 2023Article
- Surgical Strategies for Recurrent Hepatocellular Carcinoma after Resection: A Review of Current Evidence.Cancers · 2023Review
- Therapeutic strategies for post-transplant recurrence of hepatocellular carcinoma.World journal of gastroenterology · 2022Review
- Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models.Annals of transplantation · 2022Review
- Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study.Cancers · 2021Article
- Recurrence of Hepatocellular Carcinoma After Liver Transplantation is Associated with Episodes of Acute Rejections.Journal of hepatocellular carcinoma · 2021Article
- Management of Recurrent HCC After Liver Transplantation.Journal of gastrointestinal cancer · 2020Review
- Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?World journal of transplantation · 2020Review
- Obtaining Optimal Long-Term Outcomes from Liver Transplantation for Hepatocellular Cancer.Digestive diseases and sciences · 2019Review
- Hepatocellular carcinoma recurrence after liver transplantation: Risk factors, screening and clinical presentation.World journal of hepatology · 2019Review
- Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation.Journal of Korean medical science · 2018Article
- Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence.Journal of Korean medical science · 2018Article
- Late recurrence of hepatocellular carcinoma after liver transplantation.Hepatoma research · 2017Article
- Hepatocellular carcinoma (HCC) recurrence and what to do when it happens.Hepatobiliary surgery and nutrition · 2016Article
- Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation.World journal of gastroenterology · 2016Article
- Management of hepatocellular carcinoma in the elderly.World journal of hepatology · 2015Review
- Treatment for hepatocellular carcinoma in elderly patients: a literature review.Journal of Cancer · 2013Review
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough factors associated with an increased risk of recurrence after liver transplantation for hepatocellular carcinoma (HCC) have been extensively studied, the history of patients with a post-transplant recurrence is poorly known.
methodsPatients experiencing a post-transplant HCC recurrence from 1996 to 2011 in two transplant programs were included. Demographic, transplant, and post-recurrence variables were assessed.
resultsThirty patients experienced an HCC recurrence-22 men and 8 women with a mean age of 55 ± 6 years. Sixteen (53 %) were outside the Milan criteria at the time of transplantation. Most recurrences (60 %) appeared within the first 18 months after transplantation, ranging between 1.7 and 109 months (median 14.2 months). Mean post-recurrence survival was 33 ± 31 months. On univariate analysis, total tumor volume (TTV; p = 0.047), microvascular invasion (p = 0.011), and time from transplant to recurrence (p = 0.001) predicted post-recurrence survival. On multivariate analysis, both time from transplant to recurrence (p = 0.001) and history of rejection (p = 0.043), but not the location of the recurrence or the type of recurrence treatment, predicted post-recurrence survival.
conclusionThis study suggests that patients with early post-transplant HCC recurrence have worse outcomes. Those with a history of graft rejection have better survivals, possibly due to more active anti-cancer immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.